Implications of the FDA statement on transvaginal placement of mesh: the aftermath.
Curr Urol Rep
; 15(2): 380, 2014 Feb.
Article
em En
| MEDLINE
| ID: mdl-24384996
ABSTRACT
The release of the U.S. Food and Drug Administration (FDA) safety communication on the use of transvaginal mesh (TVM) for pelvic organ prolapse (POP) has resulted in changes in the pelvic reconstruction community. This monograph reviews the implications of the FDA statements over the last 18-24 months. Recent findings show that there have been significant developments in the areas of regulatory mandates, media and medico-legal activity, and statements from surgical societies. In summary, well-publicized communications from the FDA and major medical organizations are defining a change in the use of TVM for POP.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Telas Cirúrgicas
/
United States Food and Drug Administration
/
Incontinência Urinária
/
Qualidade de Produtos para o Consumidor
/
Slings Suburetrais
/
Prolapso de Órgão Pélvico
Limite:
Female
/
Humans
País/Região como assunto:
America do norte
Idioma:
En
Revista:
Curr Urol Rep
Assunto da revista:
UROLOGIA
Ano de publicação:
2014
Tipo de documento:
Article